SIBA 5'-Isobutylthioadenosine; 5'-Deoxy-5'-isobutylthioadenosine|cas:35899-54-8|西域试剂

SIBA 5'-Isobutylthioadenosine; 5'-Deoxy-5'-isobutylthioadenosine,99.66%

产品编号：Bellancom-18684| CAS NO：35899-54-8| 分子式：C₁₄H₂₁N₅O₃S| 分子量：339.41

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-18684	￥1400.00	杭州北京（现货）
Bellancom-18684	￥2000.00	杭州北京（现货）
Bellancom-18684	￥7000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SIBA 5'-Isobutylthioadenosine; 5'-Deoxy-5'-isobutylthioadenosine

产品介绍

SIBA (5'-Isobutylthioadenosine) 是一种 Transmethylation 抑制剂 (SAH (HY-19528) 类似物)，具有强大的抗增殖活性。SIBA 通过阻断甲基化，特别是阻断病毒 mRNA 的5' 端加帽，可逆地抑制 HSV-1 的产生。SIBA 还能抑制肿瘤细胞系的体外生长和体内转移扩散。SIBA 可用于癌症，HSV-1 感染和抗疟疾的研究。

生物活性

SIBA (5'-Isobutylthioadenosine) is a transmethylation inhibitor (SAH (HY-19528) analogue), with potent anti-proliferative activity. SIBA reversibly inhibits the production of HSV-1 by blocking methylation, specifically by blocking the 5' end-capping of viral mRNA. SIBA also inhibits the growth of tumour cells in vitro and metastatic spread in vivo. SIBA can be used in cancer, HSV-1 infection and anti-malaria studies.

体外研究

SIBA (0.5 mM; 24-96 h) shows strong anti-proliferative activity against 3LL and RMS-J1 tumour cells.
SIBA (1 mM; 12, 24 h) reversibly inhibits HSV production in HEp2 cells (infected by HSV-1).
SIBA inhibits protein synthesis by 98% after 10 h infection of HEp2 cells (infected by HSV-1).
SIBA (1 mM; 8.5 h) inhibits protein synthesis and RNA methylation in HEp2 cells (infected by HSV-1).
SIBA (0.5, 1.0 mM; 24, 48 h) inhibits the conversion of putrescine into spermidine and/or spermine and that this inhibition is a reversible one (interferes with polyamine biosynthesis, probably by blocking aminopropyltransferase).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	3 LL and RMS-J1 cells
Concentration:	0.5 mM
Incubation Time:	24-96 h
Result:	Inhibited 3LL and RMS-J1 tumor cell growth potently by 96% and 88%, respectively.

Cell Viability Assay

Cell Line:	HEp2 cells (infected by HSV-1)
Concentration:	1 mM
Incubation Time:	12, 24 h
Result:	Decreased virus production by 88.4 and 98.2% when at 12 and 24 h, respectively.

Cell Viability Assay

Cell Line:	HEp2 cells (infected by HSV-1)
Concentration:	1 mM
Incubation Time:	8.5 h
Result:	Reduced protein synthesis by 41.3% in normal medium and by 63.5% in medium poor in methionine. Inhibited RNA methylation by 65.4%.

Cell Viability Assay

Cell Line:	chick embryo fibroblasts
Concentration:	0.5, 1.0 mM
Incubation Time:	24, 48 h
Result:	Inhibited the uptake of the radioactive diamine and that the inhibition was dose-dependent. Markedly inhibited the formation of [¹⁴C]spermidine and [¹⁴C]spermine from [¹⁴C]putrescine. Inhibited the growth of chick embryo fibroblasts mainly after exposure for 48 h.

体内研究
(In Vivo)

SIBA (150 mg/kg; i.p.; twice weekly for 3 weeks) inhibits tumor growth in vivo.
SIBA (15 mg/kg; i.p.; thrice weekly for 4 weeks) inhibits metastatic spread of RMS-J1 cells in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 female mice (4-8 weeks old).
Dosage:	150 mg/kg
Administration:	Intraperitoneal injection; twice weekly for 3 weeks.
Result:	Significantly reduced the median number of lung metastases.

Animal Model:	Adult syngeneic Wistar AG rats (8-week-old; subcutaneously grafted with RMS-J1 cells).
Dosage:	15 mg/kg
Administration:	Intraperitoneal injection; thrice weekly for 4 weeks.
Result:	Inhibited in vivo metastatic spread of RMS-J1 cells, and showed median numbers of lung metastatic nodules was 26.

体内研究

SIBA (150 mg/kg; i.p.; twice weekly for 3 weeks) inhibits tumor growth in vivo.
SIBA (15 mg/kg; i.p.; thrice weekly for 4 weeks) inhibits metastatic spread of RMS-J1 cells in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 female mice (4-8 weeks old).
Dosage:	150 mg/kg
Administration:	Intraperitoneal injection; twice weekly for 3 weeks.
Result:	Significantly reduced the median number of lung metastases.

Animal Model:	Adult syngeneic Wistar AG rats (8-week-old; subcutaneously grafted with RMS-J1 cells).
Dosage:	15 mg/kg
Administration:	Intraperitoneal injection; thrice weekly for 4 weeks.
Result:	Inhibited in vivo metastatic spread of RMS-J1 cells, and showed median numbers of lung metastatic nodules was 26.

体内研究

SIBA (150 mg/kg; i.p.; twice weekly for 3 weeks) inhibits tumor growth in vivo.
SIBA (15 mg/kg; i.p.; thrice weekly for 4 weeks) inhibits metastatic spread of RMS-J1 cells in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 female mice (4-8 weeks old).
Dosage:	150 mg/kg
Administration:	Intraperitoneal injection; twice weekly for 3 weeks.
Result:	Significantly reduced the median number of lung metastases.

Animal Model:	Adult syngeneic Wistar AG rats (8-week-old; subcutaneously grafted with RMS-J1 cells).
Dosage:	15 mg/kg
Administration:	Intraperitoneal injection; thrice weekly for 4 weeks.
Result:	Inhibited in vivo metastatic spread of RMS-J1 cells, and showed median numbers of lung metastatic nodules was 26.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (294.63 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.9463 mL	14.7314 mL	29.4629 mL
5 mM	0.5893 mL	2.9463 mL	5.8926 mL
10 mM	0.2946 mL	1.4731 mL	2.9463 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.37 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.37 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.37 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。